Seres Therapeutics

Seres Therapeutics reported significant biomarker results from its SER-155 Phase 1b study, showing reduced fecal albumin and systemic inflammation, supporting SER-155's potential to decrease bloodstream infections by enhancing epithelial barrier integrity and impacting immune homeostasis in allo-HSCT patients, indicating benefits for inflammatory and immune diseases.

Seres Therapeutics' SER-155 showed significant reductions in bloodstream infections and systemic inflammation biomarkers in allo-HSCT patients, supporting its potential to enhance epithelial barrier integrity and immune homeostasis. The Phase 1b study results highlight SER-155's promise in reducing infections and improving outcomes for patients with hematological malignancies.

SER-155 Phase 1b study shows it enhances epithelial barrier integrity and reduces systemic inflammation in allo-HSCT patients, supporting its potential for treating inflammatory and immune diseases. Data accepted for 2025 TANDEM Meeting. SER-155's commercial potential highlighted by payer research. Seres Therapeutics extends cash runway into Q1 2026.

Seres Therapeutics' SER-155, an oral live biotherapeutic, has shown promise in reducing bloodstream infections in allo-HSCT patients, receiving FDA Breakthrough Therapy designation. Market research highlights a high unmet need for effective prophylactic options, with SER-155's potential value proposition recognized by healthcare professionals and payers. Seres plans to engage with the FDA on a registrational study and seeks partnerships to maximize SER-155's opportunity, supported by promising clinical data and a projected cash runway into 2026.

Seres Therapeutics announced new SER-155 Phase 1b study results showing improved epithelial barrier integrity and reduced systemic inflammation in allo-HSCT patients, supporting its potential in treating inflammatory and immune diseases. SER-155 also received Breakthrough Therapy designation from the FDA. The company expects its cash runway to extend into Q1 2026.

Seres Therapeutics' SER-155 Phase 1b study shows promising results in allo-HSCT recipients, enhancing epithelial barrier integrity and reducing systemic inflammation. SER-155 received Breakthrough Therapy designation for reducing bloodstream infections. Seres plans to present these findings at the 2025 TANDEM Meeting and seeks strategic partnerships to advance SER-155 development.

Seres Therapeutics, Inc. focuses on developing microbiome therapeutics to treat diseases by modulating the colonic microbiome. Its lead product, VOWST, targets recurrent Clostridioides difficile infection, with other candidates in various clinical trial phases for gastrointestinal infections and ulcerative colitis. The company collaborates with NHSc Rx License GmbH and Nestlé for product development and commercialization.

SER-155 Phase 1b study shows it enhances epithelial barrier integrity and reduces systemic inflammation in allo-HSCT patients, supporting its potential against inflammatory and immune diseases. Data accepted for 2025 TANDEM Meeting. SER-155's commercial opportunity is underscored by payer research. Seres' cash runway extends into Q1 2026.

MaaT Pharma's MaaT013, a microbiome therapy for acute graft-versus-host disease (aGvHD) with gastrointestinal involvement, showed promising results in a phase 3 trial. 62% of patients responded, with 38% achieving complete gastrointestinal response. The therapy targets the gut-immune interface, offering new hope for patients resistant to existing treatments. MaaT plans EU approval filing and is developing MaaT033 for cancer patients.